GlassScriptPhysician profile
Michael A Ciszek
NPI 1215048590
$4,143.29
in general payments reported to CMS, 2019-2025
20 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $190 · 2021: $650 · 2022: $384 · 2023: $502 · 2024: $630 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589 · Consulting Fee: $870 · Debt Forgiveness: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.68 |
| Consulting Fee | $870.10 |
| Debt Forgiveness | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,560.84 | 2019-2025 | Acuvue |
| Coopervision INC. | $431.37 | 2019-2025 | Myday Contact Lens, Onefit Contact Lens |
| Eyevance Pharmaceuticals LLC | $409.43 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $314.71 | 2022-2025 | Infuse, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $305.29 | 2019-2023 | |
| Alcon Vision LLC | $284.91 | 2019-2025 | Total30, Precision 1 |
| Oyster Point Pharma, INC. | $176.84 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.64 | 2019-2021 | |
| Biotissue Holdings INC. | $83.26 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $80.44 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $58.04 | 2019 | |
| Sun Pharmaceutical Industries INC. | $54.99 | 2022-2025 | |
| Optos, INC. | $51.30 | 2020-2023 | Panoramic Ophthalmoscope |
| Harrow Eye, LLC | $51.20 | 2024-2025 | Vevye |
| Carl Zeiss Meditec, INC. | $39.55 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30.29 | 2021-2022 | |
| Spark Therapeutics, INC. | $27.23 | 2022 | |
| Dompe US, INC. | $20.82 | 2024 | Oxervate |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $17.74 | 2024 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ciszek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.